MB
Mohit Bansal Wells Fargo Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Vertex Pharmaceuticals
VRTX
$101B
| $393.74 | $460 |
17%
upside
| Overweight |
6 Aug ‘25
1 month ago |
|
2
BioNTech
BNTX
$24.7B
| $102.84 | $150 |
46%
upside
| Overweight |
5 Aug ‘25
1 month ago |
|
3
Merck
MRK
$210B
| $84 | $90 |
7%
upside
| Equal-Weight |
30 Jul ‘25
1 month ago |
|
4
Regeneron Pharmaceuticals
REGN
$58.9B
| $555.94 | $580 |
4%
upside
| Equal-Weight |
30 May ‘25
3 months ago |
|
5
Xenon Pharmaceuticals
XENE
$2.95B
| $38.31 | $47 |
23%
upside
| Overweight |
13 May ‘25
3 months ago |
|
6
Halozyme
HALO
$8.84B
| $75.58 | $65 |
14%
downside
| Equal-Weight |
7 May ‘25
4 months ago |
|
7
Bristol-Myers Squibb
BMY
$94.7B
| $46.53 | $53 |
14%
upside
| Equal-Weight |
28 Apr ‘25
4 months ago |
|
8
Ironwood Pharmaceuticals
IRWD
$180M
| $1.11 | $1 |
10%
downside
| Equal-Weight |
15 Apr ‘25
4 months ago |
|
9
Eli Lilly
LLY
$665B
| $741.96 | $1,100 |
48%
upside
| Overweight |
5 Mar ‘25
6 months ago |
|
10
Gilead Sciences
GILD
$144B
| $115.70 | $140 |
21%
upside
| Overweight |
5 Mar ‘25
6 months ago |
|
11
AbbVie
ABBV
$369B
| $209.03 | $240 |
15%
upside
| Overweight |
5 Mar ‘25
6 months ago |
|
12
Biogen
BIIB
$20.7B
| $141.26 | $140 |
1%
downside
| Equal-Weight |
13 Feb ‘25
6 months ago |
|
13
Jazz Pharmaceuticals
JAZZ
$7.85B
| $129.46 | $170 |
31%
upside
| Overweight |
13 Feb ‘25
6 months ago |
|
14
Amgen
AMGN
$151B
| $279.88 | $280 |
0%
upside
| Equal-Weight |
10 Jan ‘25
8 months ago |
|
15
Summit Therapeutics
SMMT
$14.6B
| $19.70 | $30 |
52%
upside
| Overweight |
11 Dec ‘24
9 months ago |
|
16
Vera Therapeutics
VERA
$1.59B
| $24.92 | $70 |
181%
upside
| Overweight |
21 Nov ‘24
9 months ago |
|
17
Travere Therapeutics
TVTX
$1.89B
| $21.15 | $27 |
28%
upside
| Overweight |
21 Oct ‘24
10 months ago |
|
18
BioMarin Pharmaceuticals
BMRN
$10.8B
| $56.10 | $90 |
60%
upside
| Overweight |
17 Sep ‘24
11 months ago |
|
19
Pfizer
PFE
$139B
| $24.49 | $30 |
23%
upside
| Equal-Weight |
31 Jul ‘24
1 year ago |
|
20
Neurocrine Biosciences
NBIX
$14.3B
| $144.28 | $170 |
18%
upside
| Overweight |
24 Apr ‘24
1 year ago |
|
21
Mineralys Therapeutics
MLYS
$2.8B
| $36.16 | $27 |
25%
downside
| Overweight |
7 Mar ‘23
2 years ago |
|
|
22
Vertex Pharmaceuticals
VRTX
$101B
| $393.74 | $285 |
28%
downside
| Buy |
11 Jun ‘21
4 years ago |
|
|
23
Biogen
BIIB
$20.7B
| $141.26 | $440 |
211%
upside
| Neutral |
8 Jun ‘21
4 years ago |
|
24
Forte Biosciences
FBRX
$136M
| $10.92 | $1,875 |
17,070%
upside
| Buy |
26 Mar ‘21
4 years ago |
|
|
25
Regeneron Pharmaceuticals
REGN
$58.9B
| $555.94 | $584 |
5%
upside
| Buy |
14 Jan ‘21
4 years ago |
|